首站-论文投稿智能助手
典型文献
Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study)
文献摘要:
Background::Biological agents, such as tumor necrosis factor inhibitors (TNFi), have been widely used in rheumatoid arthritis (RA) patients and greatly improved goal achievement. The aim of this study was to investigate whether conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) combination was better in reducing relapse than methotrexate (MTX) monotherapy, and more cost-effective than continuing TNFi plus MTX in RA patients who achieved low disease activity (LDA) with TNFi and MTX therapy.Methods::RA patients who failed to csDMARDs received an induction therapy of MTX plus TNFi for maximally 12 weeks. Those achieving LDA in 12 weeks were randomly assigned at a 1:1:1 ratio into three groups: (A) adding hydroxychloroquine and sulfasalazine for the first 12 weeks and then discontinuing TNFi for the following 48 weeks; (B) maintaining TNFi and MTX for 60 weeks; and (C) maintaining TNFi and MTX for the first 12 weeks and then discontinuing TNFi for the following 48 weeks. The primary outcome was relapse.Results::A total of 117 patients were enrolled for induction therapy and 67 patients who achieved LDA within 12 weeks were randomized, with 24, 21, and 22 patients in groups A, B, and C, respectively. The relapse rates of groups A and B during the entire 60 weeks were comparable [10/22 (45.5%) vs. 7/20 (35.0%), χ 2 = 0.475, P = 0.491], however, significantly lower than that of group C [10/22 (45.5%) vs. 17/20 (85.0%), χ 2 = 5.517, P = 0.019; 7/20 (35.0%) vs. 17/20 (85.0%), χ 2 = 11.035, P = 0.004, respectively]. Taking RMB 100,000 Yuan as the threshold of willingness to pay, compared to MTX monotherapy (group C), both TNFi maintenance and triple csDMARDs therapies were cost-effective, but triple csDMARDs therapy was better. Conclusion::For RA patients who have achieved LDA with TNFi and MTX, csDMARDs triple therapy was a cost-effective option in favor of reducing relapse.Trial registration::ClinicalTrials.gov, NCT02320630.
文献关键词:
Conventional synthetic disease-modifying anti-rheumatic drugs;Cost-effectiveness;Relapse;Rheumatoid arthritis;Tumor necrosis factor inhibitors
作者姓名:
Zhao Juan;Zhou Wei;Wu Yangfeng;Yan Xiaoyan;Yang Li;Zhang Zhuoli
作者机构:
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing 100034, China;Peking University Clinical Research Institute (PUCRI), Beijing 100083, China;Peking University School of Public Health, Beijing 100083, China
引用格式:
[1]Zhao Juan;Zhou Wei;Wu Yangfeng;Yan Xiaoyan;Yang Li;Zhang Zhuoli-.Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study))[J].中华医学杂志(英文版),2022(18):2200-2209
A类:
ESCoRT,discontinuing,NCT02320630,Relapse
B类:
Efficacy,safety,cost,effectiveness,triple,preventing,relapse,rheumatoid,arthritis,randomized,controlled,trial,study,Background,Biological,agents,such,tumor,necrosis,inhibitors,TNFi,have,been,widely,used,RA,patients,greatly,improved,goal,achievement,aim,this,was,investigate,whether,conventional,synthetic,disease,modifying,anti,rheumatic,drugs,csDMARDs,combination,better,reducing,than,methotrexate,MTX,monotherapy,more,plus,who,achieved,activity,LDA,Methods,failed,received,induction,maximally,weeks,Those,achieving,were,randomly,assigned,into,three,groups,adding,hydroxychloroquine,sulfasalazine,first,then,following,maintaining,primary,outcome,Results,total,enrolled,within,respectively,rates,during,entire,comparable,however,significantly,lower,that,Taking,RMB,Yuan,threshold,willingness,pay,compared,both,maintenance,therapies,but,Conclusion,For,option,favor,registration,ClinicalTrials,gov,Conventional,Cost,Rheumatoid,Tumor
AB值:
0.434716
相似文献
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai;Meng Wang;Ting Deng;Yuxian Bai;Kai Zang;Zhanhui Miao;Wenlin Gai;Liangzhi Xie;Yi Ba-Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medical Oncology,Henan Cancer Hospital,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Oncology Department,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Sinocelltech Ltd.,Beijing 100176,China;Beijing Engineering Research Center of Protein and Antibody,Beijing 100176,China;Cell Culture Engineering Center,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China
Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04)
Sung Uk Lee;Jinsil Seong;Tae Hyun Kim;Jung Ho Im;Woo Chul Kim;Kyubo Kim;Hae Jin Park;Tae Gyu Kim;Youngkyong Kim;Bae Kwon Jeong;Jin Hee Kim;Byoung Hyuck Kim;Taek-Keun Nam-Center for Proton Therapy and Center for Liver and Pancreatobiliary Cancer,National Cancer Center,Goyang 10408,Korea;Department of Radiation Oncology,Yonsei Cancer Center,Yonsei University College of Medicine,Seoul 03722,Korea;Department of Radiation Oncology,CHA Bundang Medical Center,CHA University School of Medicine,Seongnam 13497,Korea;Department of Radiation Oncology,Inha University Hospital,Inha University School of Medicine,Incheon 22332,Korea;Department of Radiation Oncology,Ewha Womans University Mokdong Hospital,Ewha Womans University College of Medicine,Seoul 07985,Korea;Department of Radiation Oncology,Hanyang University Medical Center,Hanyang University College of Medicine,Seoul 04763,Korea;Department of Radiation Oncology,Samsung Changwon Hospital,Sungkyunkwan University School of Medicine,Changwon 51353,Korea;Department of Radiation Oncology,Kyung Hee University Hospital,Kyung Hee University College of Medicine,Seoul 02447,Korea;Department of Radiation Oncology,Gyeongsang National University Hospital,Gyeongsang National University College of Medicine,Jinju 52727,Korea;0Department of Radiation Oncology,Dongsan Medical Center,Keimyung University School of Medicine,Daegu 41931,Korea;1Department of Radiation Oncology,Seoul Metropolitan Government Seoul National University Boramae Medical Center,Seoul 07061,Korea;2Department of Radiation Oncology,Chonnam National University Hwasun Hospital,Chonnam National University College of Medicine,Hwasun 58128,Korea
Homeopathy for COVID-19 in primary care:A randomized,double-blind,placebo-controlled trial(COVID-Simile study)
Ubiratan Cardinalli Adler;Maristela Schiabel Adler;Ana Elisa Madureira Padula;Livia Mitchiguian Hotta;Amarilys de Toledo Cesar;José Nelson Martins Diniz;Helen de Freitas Santos;Edson Zangiacomi Martinez-Department of Medicine,Federal University of S?o Carlos,S?o Carlos 13565-905,Brazil;Homeopathy Solidarity Outpatient Extension Program,Mackenzie Presbyterian University,S?o Paulo 01302-907,Brazil;Municipal Center for Integrative and Complementary Practices in Health,Guarulhos 07023-051,Brazil;HN-Cristiano Institute,S?o Paulo 02013-001,Brazil;School Health Unit,Federal University of S?o Carlos,Sao Carlos 13565-905,Brazil;Federal Institute of Education,Science and Technology of S?o Paulo,Birigui 16201-407,Brazil;Department of Social Medicine,Ribeir?o Preto Medical School,University of Sao Paulo,Ribeirao Preto 14049-900,Brazil
Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation:A double-blind randomized controlled trial
Maryam Azimi;Hanieh Niayesh;Mahboobeh Raeiszadeh;Sedigheh Khodabandeh-shahraki-Gastroenterology and Hepatology Research Center,Kerman University of Medical Sciences,Kerman 7716913555,Iran;Department of Traditional Medicine,School of Persian Medicine,Kerman University of Medical Sciences,Kerman 7716913555,Iran;Student Research Committee,Afzalipour Faculty of Medicine,Kerman University of Medical Sciences,Kerman 7716913555,Iran;Herbal and Traditional Medicines Research Center,Kerman University of Medical Sciences,Kerman 7716913555,Iran;Department of Community Health Nursing,Razi Faculty of Nursing and Midwifery,Kerman University of Medical Sciences,Kerman 7716913555,Iran
Wenshen Jianpi recipe(温肾健脾方)induced immune reconstruction and redistribution of natural killer cell subsets in immunological non-responders of human immunodeficiency virus/acquired immune deficiency syndrome:a randomized controlled trial
TAO Zhuang;WANG Jian;CHEN Xin;LI Yonghong;YAN Yuguang;ZHANG Ao;ZOU Wen;LIU Ying-Research Center of AIDS Treatment with Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Institute of Basic Theory for Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Department of Integrated Traditional Chinese and Wetern Medicine,Kunming Hospital of Traditional Chinese Medicine,Kunming 650000,China;Department of Infection,No.6 People's Hospital of Shenyang City,Shenyang 110006,China;University of Chinese Academy of SoCIal SCIences,Beijing,100102,China
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail
Chen Nan;Xing Changying;Niu Jianying;Liu Bicheng;Fu Junzhou;Zhao Jiuyang;Ni Zhaohui;Wang Mei;Liu Wenhu;Zhao Jinghong;Zhong Ling;Wu Xiongfei;Li Wenge;Chen Yuqing;Shi Wei;Chen Jianghua;Yin Aiping;Fu Ping;Wang Rong;Jiang Gengru;Hou Fanfan;Ding Guohua;Chen Jing;Xu Gang;Kondo Yuichiro;Su Yuliang;Mei Changlin-Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd, Tokyo 520-5292, Japan;D&R office, Kyowa Kirin China Pharmaceutical Co., Ltd, Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial
Liu Bicheng;Chen Nan;Zhao Jinghong;Yin Aiping;Wu Xiongfei;Xing Changying;Jiang Gengru;Fu Junzhou;Wang Mei;Wang Rong;Niu Jianying;Fu Ping;Ni Zhaohui;Hou Fanfan;Zhao Jiuyang;Chen Jing;Chen Yuqing;Shi Wei;Chen Jianghua;Li Wenge;Xu Gang;Zhong Ling;Liu Wenhu;Ding Guohua;Kondo Yuichiro;Yue Changhe;Mei Changlin-Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd., Tokyo 520-5292, Japan;D&R Office, Kyowa Kirin China Pharmaceutical Co., Ltd., Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China
Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients
Minghui Li;Fangfang Sun;Xiaoyue Bi;Yanjie Lin;Liu Yang;Yao Lu;Lu Zhang;Gang Wan;Wei Yi;Linqing Zhao;Yao Xie-Department of Hepatology Division 2,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China;Department of Hepatology Division 2,Peking University Ditan Teaching Hospital,Beijing 100015,China;Department of Biostatistics,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China;Department of Gynecology and Obstetrics,Beijing Ditan Hospital,Capital Medical University,Beijing,100015,China;Laboratory of Virology,Beijing Key Laboratory of Etiology of Viral Diseases in Children,Capital Institute of Pediatrics,Beijing,100020,China
Anlotinib as third-or further-line therapy for short-term relapsed small-cell lung cancer:subgroup analysis of a randomized phase 2 study(ALTER1202)
Jianhua Shi;Ying Cheng;Qiming Wang;Kai Li;Lin Wu;Baohui Han;Gongyan Chen;Jianxing He;Jie Wang;Haifeng Qin;Xiaoling Li-Department of Medical Oncology,Linyi Cancer Hospital,Linyi 276002,China;Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130012,China;Department of Internal Medicine,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450003,China;Department of Pulmonary Oncology,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Thoracic Medical Oncology,The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University(Hunan Cancer Hospital),Changsha 410031,China;Department of Respiratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Thoracic Surgery,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Pulmonary Oncology,The Fifth Medical Centre of Chinese PLA General Hospital,Beijing 100039,China;Department of Medical Oncology,Liaoning Cancer Hospital,Shenyang 110042,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。